Tag Archives: Cell

Cannabis shows potential for mitigating sickle cell disease pain

Cannabis appears to be a safe and potentially effective treatment for the chronic pain that afflicts people with sickle cell disease, according to a new clinical trial co-led by University of California, Irvine researcher Kalpna Gupta and Dr. Donald Abrams of UC San Francisco. The findings appear in JAMA Network Open. “These trial results show… Read More »

Brukinsa Approved for Relapsed, Refractory Mantle Cell Lymphoma

MONDAY, Nov. 18, 2019 — Brukinsa (zanubrutinib), a kinase inhibitor, has been granted accelerated approval for the treatment of adults with mantle cell lymphoma who have received at least one previous therapy, the U.S. Food and Drug Administration announced last week. The recommended dose of Brukinsa capsules is 160 mg orally twice daily or 320… Read More »

FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions

FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions Print this page SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the… Read More »

High-cost Gilead cell therapy proves durable for some lymphoma patients

SAN DIEGO (Reuters) – Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May 1,… Read More »